Lafora DiseaseSymptoms, Doctors, Treatments, Advances & More
Lafora Disease Overview
Learn About Lafora Disease
- Lafora disease
- EPM2
- Epilepsy progressive myoclonic 2
- Lafora body disorder
- MELF
- Myoclonic epilepsy of Lafora
Samuel Berkovic practices practicing medicine in Heidelberg, Australia. Mr. Berkovic is rated as an Elite expert by MediFind in the treatment of Lafora Disease. He is also highly rated in 48 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Epilepsy, Partial Familial Epilepsy, and Epilepsy with Myoclonic-Atonic Seizures.
Reetta Kalviainen practices practicing medicine in Kuopio, Finland. Kalviainen is rated as an Elite expert by MediFind in the treatment of Lafora Disease. They are also highly rated in 14 other conditions, according to our data. Their clinical expertise encompasses Unverricht-Lundborg Syndrome, Dentatorubral-Pallidoluysian Atrophy, Lafora Disease, and Myoclonic Epilepsy.
Laura Canafoglia practices practicing medicine in Milan, Italy. Ms. Canafoglia is rated as an Elite expert by MediFind in the treatment of Lafora Disease. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Dentatorubral-Pallidoluysian Atrophy, Lafora Disease, Epilepsy with Myoclonic-Atonic Seizures, Myoclonic Epilepsy, and Gastrostomy.
Summary: The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and facilitate natural history studies, definition of outcome measures and conduction of clinical trials.
Summary: The Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1) is focused on gathering longitudinal clinical data as well as biological samples (blood and/or urine) from male and female patients, of all ages, who have a molecular diagnosis of EPM1or CSTB-null-related disease. Currently, there are no therapies that halt disease progression in any CSTB-related diseases, high...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center